Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Biocon has reported consolidated financial results for the period ended December 31, 2021
Decisions reaffirm the ability of Biocon Biologics and Viatris to provide patient access to interchangeable Semglee
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
At present 18 per cent of the local pharmaceutical market is under government's price control
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
